Skip to main content
NCBI home page
Transactions of the American Clinical and Climatological Association logoLink to Transactions of the American Clinical and Climatological Association
. 2004;115:395–404.

Cyclosporin a aerosol improves the anticancer effect of Paclitaxel aerosol in mice.

Vernon Knight, N V Koshkina, E Golunski, L E Roberts, B E Gilbert
PMCID: PMC2263789  PMID: 17060982

Abstract

Paclitaxel (PTX) is a lipophilic agent with broad anticancer activity. In the present study we examined the antitumor effect and toxicity of co-administration of cyclosporine A (CsA) and PTX in liposomal aerosol using the Renca lung metastases mouse model. The untreated and PTX-only groups exhibited cancer growth while CsA aerosol plus PTX had more favorable effects on tumor growth. Weight loss was seen in mice treated with CsA/PTX+CsA by day 9 to 22. Histopathological examination showed no toxicity following treatment. The findings offer evidence that a combination of CsA and PTX may be suitable for aerosol treatment of lung cancer if it is possible to control toxicity of the therapy.

Full text

PDF
395

Images in this article

399Fig. 1
on p.399

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cabanes A., Briggs K. E., Gokhale P. C., Treat J. A., Rahman A. Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel. Int J Oncol. 1998 May;12(5):1035–1040. doi: 10.3892/ijo.12.5.1035. [DOI] [PubMed] [Google Scholar]
  2. Choy H., MacRae R. The current state of paclitaxel and radiation in the combined-modality therapy of non-small cell lung cancer. Semin Oncol. 2001 Aug;28(4 Suppl 14):17–22. doi: 10.1016/s0093-7754(01)90055-7. [DOI] [PubMed] [Google Scholar]
  3. Cresteil T., Monsarrat B., Alvinerie P., Tréluyer J. M., Vieira I., Wright M. Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res. 1994 Jan 15;54(2):386–392. [PubMed] [Google Scholar]
  4. Fairchild G. A. Measurement of respiratory volume for virus retention studies in mice. Appl Microbiol. 1972 Nov;24(5):812–818. doi: 10.1128/am.24.5.812-818.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fujitaka K., Oguri T., Isobe T., Fujiwara Y., Kohno N. Induction of cytochrome P450 3A4 by docetaxel in peripheral mononuclear cells and its expression in lung cancer. Cancer Chemother Pharmacol. 2001 Jul;48(1):42–46. doi: 10.1007/s002800100291. [DOI] [PubMed] [Google Scholar]
  6. Germann U. A. Detection of recombinant P-glycoprotein in multidrug resistant cultured cells. Mol Biotechnol. 2000 Feb;14(2):131–145. doi: 10.1385/MB:14:2:131. [DOI] [PubMed] [Google Scholar]
  7. Gilbert B. E., Knight C., Alvarez F. G., Waldrep C., Rodarte J. R., Knight V., Eschenbacher W. L. Tolerance of volunteers to cyclosporine A-dilauroylphosphatidylcholine liposome aerosol. Am J Respir Crit Care Med. 1997 Dec;156(6):1789–1793. doi: 10.1164/ajrccm.156.6.9702101. [DOI] [PubMed] [Google Scholar]
  8. Gottesman M. M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 1993;62:385–427. doi: 10.1146/annurev.bi.62.070193.002125. [DOI] [PubMed] [Google Scholar]
  9. Koshkina N. V., Gilbert B. E., Waldrep J. C., Seryshev A., Knight V. Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice. Cancer Chemother Pharmacol. 1999;44(3):187–192. doi: 10.1007/s002800050966. [DOI] [PubMed] [Google Scholar]
  10. Koshkina N. V., Kleinerman E. S., Waidrep C., Jia S. F., Worth L. L., Gilbert B. E., Knight V. 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin Cancer Res. 2000 Jul;6(7):2876–2880. [PubMed] [Google Scholar]
  11. Koshkina N. V., Knight V., Gilbert B. E., Golunski E., Roberts L., Waldrep J. C. Improved respiratory delivery of the anticancer drugs, camptothecin and paclitaxel, with 5% CO2-enriched air: pharmacokinetic studies. Cancer Chemother Pharmacol. 2001 May;47(5):451–456. doi: 10.1007/s002800000230. [DOI] [PubMed] [Google Scholar]
  12. Koshkina N. V., Waldrep J. C., Roberts L. E., Golunski E., Melton S., Knight V. Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res. 2001 Oct;7(10):3258–3262. [PubMed] [Google Scholar]
  13. Meerum Terwogt J. M., Malingré M. M., Beijnen J. H., ten Bokkel Huinink W. W., Rosing H., Koopman F. J., van Tellingen O., Swart M., Schellens J. H. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res. 1999 Nov;5(11):3379–3384. [PubMed] [Google Scholar]
  14. Ross H. J., Canada A. L., Slater L. M. Cyclosporin A enhances paclitaxel toxicity against leukemia and respiratory epithelial cancers. Clin Cancer Res. 1997 Jan;3(1):57–62. [PubMed] [Google Scholar]
  15. Rowinsky E. K., Donehower R. C. Paclitaxel (taxol) N Engl J Med. 1995 Apr 13;332(15):1004–1014. doi: 10.1056/NEJM199504133321507. [DOI] [PubMed] [Google Scholar]
  16. Sakai H., Yoneda S., Tamura T., Nishiwaki Y., Yokoyama A., Watanabe K., Saijo N. A phase II study of paclitaxel plus cisplatin for advanced non-small-cell lung cancer in Japanese patients. Cancer Chemother Pharmacol. 2001 Dec;48(6):499–503. doi: 10.1007/s002800100374. [DOI] [PubMed] [Google Scholar]
  17. Schiff P. B., Horwitz S. B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A. 1980 Mar;77(3):1561–1565. doi: 10.1073/pnas.77.3.1561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Sharma A., Mayhew E., Bolcsak L., Cavanaugh C., Harmon P., Janoff A., Bernacki R. J. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int J Cancer. 1997 Mar 28;71(1):103–107. doi: 10.1002/(sici)1097-0215(19970328)71:1<103::aid-ijc17>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  19. Sikic B. I., Fisher G. A., Lum B. L., Halsey J., Beketic-Oreskovic L., Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol. 1997;40 (Suppl):S13–S19. doi: 10.1007/s002800051055. [DOI] [PubMed] [Google Scholar]
  20. Sonnichsen D. S., Liu Q., Schuetz E. G., Schuetz J. D., Pappo A., Relling M. V. Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther. 1995 Nov;275(2):566–575. [PubMed] [Google Scholar]
  21. Sood A. K., Sorosky J. I., Squatrito R. C., Skilling J. S., Anderson B., Buller R. E. Cyclosporin A reverses chemoresistance in patients with gynecologic malignancies. Neoplasia. 1999 Jun;1(2):118–122. doi: 10.1038/sj.neo.7900019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Sugawara I., Akiyama S., Scheper R. J., Itoyama S. Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP. Cancer Lett. 1997 Jan 15;112(1):23–31. doi: 10.1016/S0304-3835(96)04542-9. [DOI] [PubMed] [Google Scholar]
  23. Wandel C., Kim R. B., Kajiji S., Guengerich P., Wilkinson G. R., Wood A. J. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res. 1999 Aug 15;59(16):3944–3948. [PubMed] [Google Scholar]
  24. Weiss R. B., Donehower R. C., Wiernik P. H., Ohnuma T., Gralla R. J., Trump D. L., Baker J. R., Jr, Van Echo D. A., Von Hoff D. D., Leyland-Jones B. Hypersensitivity reactions from taxol. J Clin Oncol. 1990 Jul;8(7):1263–1268. doi: 10.1200/JCO.1990.8.7.1263. [DOI] [PubMed] [Google Scholar]
  25. Yokoyama H., Ishida T., Sugio K., Inoue T., Sugimachi K. Immunohistochemical evidence that P-glycoprotein in non-small cell lung cancers is associated with shorter survival. Surg Today. 1999;29(11):1141–1147. doi: 10.1007/BF02482262. [DOI] [PubMed] [Google Scholar]
  26. Younes E., Haas G. P., Dezso B., Ali E., Maughan R. L., Kukuruga M. A., Montecillo E., Pontes J. E., Hillman G. G. Local tumor irradiation augments the response to IL-2 therapy in a murine renal adenocarcinoma. Cell Immunol. 1995 Oct 15;165(2):243–251. doi: 10.1006/cimm.1995.1211. [DOI] [PubMed] [Google Scholar]

Articles from Transactions of the American Clinical and Climatological Association are provided here courtesy of American Clinical and Climatological Association

RESOURCES